The Global biosimilar market is expected to reach $23.93 Billion by 2024 from $5.91 Billion in 2017, at a CAGR of 31.8% during the forecast period. Drivers that are influencing the market are favourable intervention from the developing economies and lower cost biosimilar drugs than original biologics which helps to boost the market growth. High initial investment in research and development and stringent regulatory requirements to adversely affect investments in biosimilar are the factors which hamper the market growth. Major opportunities in this market are emerging economies and emergence of bio-better drugs which helps in market demand in future.
Research Study Objectives:
- Define, estimate, and forecast the Biosimilars market statistics by product, type of manufacturing, disease and regions concerning the individual growth drivers, market trends and their contribution toward the Biosimilars market growth
- Provides comprehensive information regarding the key factors influencing the market growth (Drivers, Restraints & Challenges, and Opportunities)
- Estimate & forecast the market size of all the segments concerning geographies including North America, Europe, Asia Pacific (APAC), South America and the Middle East and Africa (MEA).
- Recent competitive developments including M&A (Mergers and Acquisitions), Partnerships, and Product Innovations are provided in the Biosimilars Market Analysis
- Analysis and conclusions on the future Biosimilars market outlook.
Top-down and bottom-up approaches are used to validate the Biosimilars Market Size and are used to estimate the size of other dependent submarkets. Key players in the market are identified through various secondary sources; databases including Bloomberg Businessweek, Hoovers, Factiva, journals and associations and the market revenues are estimated and are thoroughly validated through primary and secondary
research. Secondary research involves the study of annual and financial reports of top players in the market, whereas primary research includes extensive interviews with the KoL’s such as CEOs, directors, board members, VP’s, sales managers, engineers, marketing executives, technicians, account managers, investors, strategic decision makers and others. The Biosimilars Market shares and breakdowns are determined using secondary sources and are verified by the primary sources. All possible parameters/factors that are affecting the Biosimilars market demand are covered in the research study are verified through primary research, analysed and interpreted to get the final qualitative and quantitative data. This data is collected and added with detailed analysis from Envision Inteligence and presented in this report.
The scope of the Report
The Biosimilars market segmentation is as follows:
By Product
- Recombinant glycosylated proteins
- Recombinant peptides
- Recombinant non-glycosylated proteins
By Type of Manufacturing
- In-house manufacturing
- Contract manufacturing
By Disease
- Oncology
- Autoimmune diseases
- Chronic diseases
- Blood disorders
- Growth hormone deficiency
- Infectious diseases
- Other diseases
Geographical Analysis:
Biosimilars market is segmented by geography into North America, South America, Europe, APAC and Middle East & Africa. U.S., Canada, Mexico and Costa Rica are analysed under North American region which is usually turning as the hotspot in the market. The South American region is further segregated into Brazil, Argentina, Chile, Columbia and some other emerging economies. In Europe, the market is extensively examined by covering U.K., Germany, France, Italy, Spain, Netherlands, Poland, Switzerland and some other promising economies. APAC is further categorised by countries into China, India, Japan, South Korea, Australia & New Zealand, Malaysia, Singapore and many other emerging nations. In the Middle East & African region, Saudi Arabia,
UAE, Iran, Iraq, Qatar, South Africa, Algeria, Morocco, Nigeria and so on countries are evaluated to understand the market growth lucidly.
Customization Options:
With the given research report, Envision Inteligence offers customisations as per the client’s specific requirements. The following customisation options offered for the Biosimilars Market include:
- Scope Revision
- Geographic Analysis
- Company Profiles
- Historical Data & Forecasting
- Key Contact Persons in companies
Global Biosimilars Market Research Report Includes:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have a complete market analysis through industry value chain analysis, Porter’s Five Force Model, PESTLE, SWOTanalysis, and Y-o-Y analysis.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
- Identifying DROC in the current market and their impact on altering market dynamics.
- Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- Identify the latest developments, market shares and strategies that are employed by the significant Biosimilars market players, such as
- Cerner Corporation.
- IBM Corporation
- Aetna, Inc.
- McKesson Corporation.
- All scripts Healthcare Solutions, Inc.
- Along with these companies, many other companies are considered in the report while analysing the Global Biosimilars competitive strategies and environment. These companies held substantial share-owning to the nature of the industry whereas, the rest of the market shares are marginal chunks to regional and local level manufacturers. Other players also have considerable presence owing to its robust brand image, geographical reach and stable customer base.
